Abstract: This invention relates to novel surface modified viral capsids and recombinant virions comprising the same. Furthermore, this invention concerns intermediates for the preparation of surface modified viral capsids. The surface modified viral capsids are designed to selectively and/or more efficiently deliver gene therapy. The surface modified viral capsids, when incorporated into a recombinant virion, can be used to treat an illness that is characterized by genetic abnormality.

Abstract: Polynucleotides and vectors can be used for the expression of a transgene in cells, such as liver cells. The expression of the transgene from the polynucleotides and vectors can be useful in gene therapy. Various methods can be used for expressing the transgene from the polynucleotides and vectors in liver cells.

Abstract: The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAP?. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAP? to which PP2A binds.

Abstract: The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.

Abstract: The present disclosure relates to magnetic resonance imaging (MRI) methods comprising (i) obtaining a baseline chemical exchange saturation transfer (CEST) MRI image of a patient, (ii) administering an effective amount of a non-nutritive sweetener to the patient, and (iii) obtaining one or more test CEST MRI image of the patient subsequent to the administering step (ii); wherein the step (i) and (iii) acquisition parameters are substantially the same. The non-nutritive sweetener may include a natural or artificial sugar alcohol, polyol, or combinations or derivatives thereof.

Abstract: Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?) and their use in imaging and treating FAP-? related diseases and disorders are disclosed.

Abstract: A personal cleansing soap bar composition is provided, comprising: a soap; an aqueous ethylene acrylic acid copolymer dispersion; a silicone copolymer emulsion with an internal phase viscosity at 25° C. of ?100×106 mm2/sec; wherein the personal cleansing soap bar is a solid.

Abstract: Disclosed are an oil-dispersed composition and a cosmetic for lip care manufactured using the same. The oil-dispersed composition includes a water-soluble raw material, an ester oil including a glyceryl group and/or an isostearyl group, a paste, and a thickener, wherein the paste and thickener are included in an amount of greater than or equal to about 30 wt % based on the total amount of the oil-dispersed composition.

Abstract: The present invention relates to a composition, in particular cosmetic, in the form of an oil-in-water emulsion, comprising a continuous aqueous phase and a dispersed oil phase in the form of drops (G1) and drops (G2), wherein the size of the drops (G1) is less than 500 ?m and the size of the drops (G2) is greater than 500 ?m.

Abstract: The present invention relates to a hair cosmetic composition, especially for washing and/or conditioning hair, comprising surfactants and an oil-in-water emulsion that comprises: a silicone mixture comprising a trialkylsilyl terminated dialkylpolysiloxane and an amino silicone; a mixture of emulsifiers comprising one or more nonionic emulsifier, wherein the mixture of emulsifiers has a HLB value from 10 to 16; and water. The invention also relates to a process for the cosmetic treatment of hair, preferably for washing and/or conditioning hair, using this composition.

Abstract: A kit includes a multi-phase oral composition for whitening teeth and an electromagnetic radiation source. The multi-phase oral composition for whitening teeth includes from about 0.002% to about 30%, by weight of the multi-phase oral composition, of a discontinuous aqueous phase having a bleaching agent, where a concentration of the bleaching agent is up to 10%, by weight of the multi-phase oral composition, and at least about 50%, by weight of the multi-phase oral composition, of a continuous hydrophobic phase of petrolatum. The electromagnetic radiation source is capable of directing electromagnetic radiation with one or more wavelength in the range from about 200 nm to about 1700 nm toward at least one tooth. The electromagnetic radiation source emits electromagnetic radiation in a range from about 100 mW/cm2 to about 250 mW/cm2.

Abstract: ABSTRACT A cosmetic composition for skin containing a solvent A, a solvent B, and a polymer C, where a boiling point of the solvent A is lower than 99° C., and a distance Ra of the Hansen solubility parameter of the solvent A to water is 36 or less; a boiling point of the solvent B is 150° C. or higher, and a distance Ra of the Hansen solubility parameter of the solvent B to water is 40 or more; and the solvent B is compatible with the solvent A, and the polymer C is soluble in the solvent A but insoluble in the solvent B. A cosmetic coating film for skin includes the cosmetic composition.

Abstract: Suggested is an antimicrobial mixture comprising or consisting of (a) at least one monocyclic sesquiterpene alcohol, (b) at least one active selected from the group consisting of 4-hydroxyacetophenone, sorbitan caprylate, cocamidopropyl PG-dimonium chloride phosphate, tetrasodium glutamate diacetate, glyceryl caprylate and glyceryl caprate, and optionally (c) at least one additional antimicrobial agent different from components (a) and (b).

Abstract: The various aspects presented herein relate to the cooling and flavor boosting compositions, and their use thereof.

Abstract: A process and a kit-of-parts for dyeing keratinous material, such as human hair, are provided. An exemplary process for dyeing keratinous material includes applying an agent (a) to the keratinous material. Agent (a) includes (a1) at least one organic silicon compound selected from the group consisting of silanes having one, two or three silicon atoms, and (a2) at least one first colorant compound comprising at least one pigment based on a lamellar substrate platelet. The method further includes applying an agent (b) to the keratinous material. Agent (b) includes (b1) at least one film-forming polymer, and (b2) at least one second colorant compound selected from the group consisting of pigments and/or direct dyes.

Abstract: Disclosed herein are skin care compositions, comprising vitamin E (e.g., alpha-tocopherol), a thiourea derivative of histidine (e.g., ergothioneine), a vitamin B3 compound (e.g., niacinamide) and/or a pyrrolidone carboxylic acid and/or a salt thereof (e.g., sodium PCA) as well as to methods of using these compositions.

Abstract: The instant disclosure relates to hair cosmetic compositions that impart desirable cosmetic properties to hair, in particular, curly hair. The hair cosmetic compositions typically include a nonionic gum, a cationic guar gum, a cationic cellulosic quaternary ammonium compound, an acrylate-based polymer, a polyol and water.

Abstract: A benefit agent delivery system whereby benefit agents can be delivered on demand and/or a variety of different benefit agents at different concentrations can be delivered from the same system. The benefit agent delivery system includes a microcell layer comprising a plurality of microcells, wherein the microcells are filled with a carrier and a benefit agent. The microcells include an opening, wherein the opening is spanned by a sealing layer comprising a polymer and metallic material. Application of an electric field across the microcell layer and the sealing layer results in the migration of the metallic material from the sealing layer and the creation of a porous sealing layer, allowing the benefit agent to be released from the benefit agent delivery system.

Abstract: A benefit agent delivery system whereby benefit agents can be delivered on demand and/or a variety of different benefit agents at different concentrations can be delivered from the same system. The benefit agent delivery system includes a microcell layer comprising a plurality of microcells, wherein the microcells are filled with a carrier and a benefit agent. The microcells include an opening, wherein the opening is spanned by a sealing layer comprising a polymer and metallic material. Application of an electric field across the microcell layer and the sealing layer results in the migration of the metallic material from the sealing layer and the creation of a porous sealing layer, allowing the benefit agent to be released from the benefit agent delivery system.

Abstract: The present disclosure relates to injectable compositions sterile injectable fluid compositions comprising a polysaccharide having a color in the visible spectrum, methods of forming the same, kits containing the same, and methods for performing agent-assisted procedures in a patient using the same.

Abstract: Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

Abstract: Described herein, inter alia, are peptide containing polymers, and methods of making and using the same.

Abstract: Given developing resistance of tumor cells to current chemotherapeutic and targeted therapeutic agents, novel cancer therapies with enhanced potency and specificity are substantially required. Applicant has provided herein extracellular nanoparticle vesicles that redirect immune effector cells towards cancer cells for killing. Relative to conventional immunotherapeutic antibodies with defined orientation and geometry for their distinct antigen-binding arms, antibodies displayed on spherical exosomes can promote formation of immunological synapses as well as enhanced efficacy to activate immune cells.

Abstract: Provided is an anesthetic composition for locally administering a local anesthetic agent to a subject in need thereof. The anesthetic composition has a lipid based complex prepared by hydrating a lipid cake containing a local anesthetic agent and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more robust for large-scale manufacture and for providing a high molar ratio of local anesthetic agent to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.

Abstract: Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and/or strains of infectious agents.

Abstract: The present application relates to a pregabalin sustained release composition, comprising: (a) an active ingredient; (b) a matrix-forming agent; (c) a swelling agent; (d) a gelling agent; and optionally a filler. The pregabalin sustained release composition provided in the present application can rapidly swell in volume when exposed to aqueous medium until exceeding the dimeter of human gastric pyloric (13 mm). It thereby prolongs the gastric emptying time to increase the retention time of pregabalin in the stomach and enhances absorption of pregabalin in the small intestine and ascending colon. Moreover, the pregabalin sustained release composition provided herein achieves a sustained release for 24 h, which allows QD (once a day) administration, reduces administration number, and improves patient compliance.

Abstract: Drug delivery using bio-affecting drugs, particularly with shape changing drug delivery devices. Embodiments are included for depots for delivery of a therapeutic agent that change from an elongated state ex vivo to a coil in vivo where the agent is released.

Abstract: A 12-hour anti-tussive modified release solid tablet or tablet-in-capsule is described which comprises a benzonatate-silicon dioxide adsorbate powder in a hydrophilic matrix to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 1% release of the benzonatate within half an hour as determined in an in vitro dissolution assay.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates generally to compositions and methods comprising abiotic, synthetic polymers with affinity and specificity to proteins. The synthetic polymers are an improvement over biological agents by providing a simpler, less expensive, and customizable platform for binding to proteins. In one embodiment, the compositions and methods relate to synthetic polymers with affinity and specificity to vascular endothelial growth factor (VEGF). In one embodiment, the compositions are useful for treating diseases and disorders related to the overexpression of VEGF. In one embodiment, the compositions are useful for treating cancer. In one embodiment, the compositions are useful for detecting VEGF levels from biological samples. In one embodiment, the compositions are useful for detecting overexpression of VEGF from biological samples. In one embodiment, the compositions are used to diagnose cancer.

Abstract: A method of producing lipid-encapsulated RNA nanoparticles includes flowing an aqueous solution comprising an RNA through a 1st tube having a first inner diameter (ID); the RNA comprises from about 6,000 to about 13,000 nucleotides; flowing an ethanol solution comprising lipids through a 2nd tube having a second inner diameter (ID), at a flow rate of about 0.2 to about 1 times relative to the aqueous solution through the 1st tube, the lipids comprise a cationic lipid; and mixing the ethanol solution with the aqueous solution; the first ID and second ID and flow rates through the 1st tube and 2nd tube are selected to produce a shear force sufficiently low to preserve the integrity of the RNA; the mixing produces an output solution flowing in the 1st tube comprising a turbulent flow of the RNA and the lipids in between about ethanol, the lipid-encapsulated RNA nanoparticles having a bilayer structure.

Abstract: A device for delivery of a first therapeutic agent and a second therapeutic agent to a site in epithelial tissue includes a first layer having a first, freeze-dried polymeric matrix having first and second opposed surfaces, formed by a composition including chitosan, a hydration promoter, a particle adhesion inhibitor, and a particle aggregation inhibitor, and a plurality of first particles embedded within the first matrix so as to be directly surrounded by, and in contact with, the first matrix, the first particles containing the first therapeutic agent and having a coating around the first therapeutic agent, the coating including chitosan. The device further includes a second layer, adjacent to the first layer, having a second, freeze-dried polymeric matrix containing the second therapeutic agent, the first layer and/or the second layer is configured to be attached to the site in the epithelial tissue.

Abstract: A hemostatic material is described, which eliminates the risks of conventional chitosan-derived products, such as the onset of shellfish allergy and endotoxin contamination, can be used safely for more people, and has an antibacterial property and a hemostatic function that widely-used hydrogels lack, and a wound dressing containing the same. A hemostatic material containing cationized cellulose and a wound dressing containing the hemostatic are described. At least one of hydroxyl groups of the cationized cellulose is modified with —R2—N+(R3)(R4)(R5).X?, other hydroxyl groups of the cationized cellulose have —H, or —(CH2CH2O)m—H, R2 represents C1-6 alkylene, C2-6 hydroxyalkylene, —(CH2CH2O)1—, or a combination thereof, 1 represents 1 or 2, m represents 1 or 2, and X? may represent an anionic group.

Abstract: A curable composition apportioned between at least one Part A and at least one Part B, the Parts sealed within barrier means in manner to prevent contamination thereof, the composition comprising: (i) one or more alkenyl-containing prepolymers having at least one alkenyl moiety per molecule, (ii) one or more SiH-containing prepolymers having at least one SiH unit per molecule, and additionally: (iii) a catalyst for curing by addition of alkenyl-containing prepolymer (i) to SiH-containing prepolymer (ii), wherein the at least one Part A and at least one Part B are provided within or upon at least two respective receptacles or supports and are adapted to be dispensed or released therefrom in cooperative manner facilitating intimate contact and curing thereof, wherein the receptacle(s) or support(s) for at least one of Part A and Part B is thermally stable at elevated temperature of 123 C for a period in excess of 18 hours, methods for preparing the composition, methods for sterilisation thereof, medical and

Abstract: The present invention relates to an X-ray irradiator for single blood bags, comprising: an X-ray irradiator main body provided with a chamber configured to safely hold a single blood bag therein and an X-ray tube configured to irradiate the chamber with X-rays; a loading part configured to load the blood bag; and a transfer part configured to transfer the blood bag between the loading part and the chamber to which X-rays are to be emitted. The X-ray irradiator for single blood bags according to the present invention can treat a single blood bag with X-rays, such that treatment optimized for a small amount of a blood bag can be performed, and a system configuration can be simplified by using an X-ray tube.

Abstract: 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof.

Abstract: A sanitizing system and method are configured to disinfect at least one surface within an area. The sanitizing system and method include a lighting assembly configured to emit disinfecting visible light onto the at least one surface. The disinfecting visible light is configured to neutralize microorganisms on the at least one surface.

Abstract: Embodiments of the invention are directed to a self-sanitizing structure that includes a body region having a contact surface that can be contacted by a person during an intended use of the self-sanitizing structure. The self-sanitizing structure further includes an energy source configured to generate electromagnetic radiation and direct the electromagnetic radiation through the body region to the contact surface. The body region is configured to scatter the electromagnetic radiation and pass the scattered electromagnetic radiation to the contact surface in a manner that maintains the scattered electromagnetic radiation that reaches the contact surface as sanitizing electromagnetic radiation. The sanitizing electromagnetic radiation is electromagnetic radiation that is at or above a minimum irradiance level that neutralizes infectious agents.

Abstract: A dressing is used for curing a wound, and includes a dressing body having a first plane to make contact with a wound of a patient and a second plane opposite to the first surface, a display unit provided on the second plane to display information, and having a flexibility, and a light irradiation device to apply light the wound of the patient. The light irradiation device includes a device board, at least one light emitting diode mounted on the device board, and a water-proof protective film provided on the light emitting diode to protect the light emitting diode.

Abstract: A sanitizer and a method for using a sanitizer are disclosed. The sanitizer comprises an illumination source, a collection frame, a discharge frame and a carrier system comprising a pair of belts to transport the elongated item between the collection frame and the discharge frame. The elongated item may be a writing instrument, a stylus, an eating utensil, or any other elongated object.

Abstract: A disinfection system is provided. The disinfection system may utilize ultraviolet light and/or ozone for disinfection of infected tissue. For example the system may involve an endoscopic ultraviolet light to disinfect lung tissue. In another aspect, the system may involve a ventilator which provides ozone in small doses to disinfect the tissue. Combinations and variations are further disclosed.

Abstract: A sterilizing apparatus is disclosed. A sterilizing apparatus according to one embodiment comprises: a cover main body unit having an accommodation space formed therein so as to accommodate a device to be sterilized, wherein the accommodation space is open toward a bottom surface on which the device to be sterilized is disposed; an ultraviolet light emitting diode provided on a surface facing the bottom surface of the cover main body unit, and turned on so as to emit ultraviolet rays toward the accommodation space; a power supply unit for supplying power to the ultraviolet light emitting diode so as to turn on the ultraviolet light emitting diode; and a control unit for controlling an operation of the power supply unit.

Abstract: An autonomous, mobile robotic device (AMR) is configured with one or more UVC radiation sources, and operates to traverse a path while disinfecting an interior space. Each UVC radiation source is connected to the AMR by an articulating arm that is controlled to orient each source towards a feature or surface that is selected for disinfection during the time that the AMR is moving through the space. The location of each feature selected for disinfection can be mapped, and this map information, a current AMR location and pose can be used to generate signals that are used to control the articulating arm to orient each UVC lamp towards a feature that is selected for disinfection.

Abstract: An Air Quality Control Lighting Device incorporating a purification device in combination with a lighting device having a LED light panel, a cover installed above the light panel, the interior of the cover forms a cavity that encloses an air UV purification device, and the air UV purification device consisting of a plurality of UV lamps mounted atop the LED light panel.

Abstract: A method of reducing malodor on surfaces including providing an apparatus in an environment including a surface wherein the surface has a malodor containing compound selected from: amine-containing compound and thiol-containing compound. The apparatus includes a volatile material having a volatile carbonyl containing compound. The volatile material is exposed to the environment such that the volatile carbonyl containing compound vaporises and deposits on the surface. The carbonyl containing compound undergoes a nucleophilic addition in the presence of the malodor containing compound.

Abstract: Mobile decontamination systems and microwave assisted decontamination methods for decontaminating a variety of contaminated surfaces disposed external to the system are disclosed. The systems and methods comprise treating the surfaces with benign chemical formulations followed by exposing to microwave irradiation for short periods of time to achieve at least 6-log reduction in biological contaminants including viruses and spores of B. anthracis, B. thuringiensis, and P. roqueforti. The formulations comprise a percarbonate and surfactant in water.

Abstract: A heat treatment method for improving the mechanical property and the biofunctional stability of a magnesium alloy is provided, comprising: (1) fully annealing an original cold-drawn magnesium alloy AZ31; (2) polishing a surface of the magnesium alloy AZ31 from the step (1) by a waterproof abrasive paper; (3) heating the magnesium alloy AZ31 obtained from the step (2) to a temperature of 330° C. to 350° C. and keeping the temperature for 3 to 4 hours; and (4) cooling the magnesium alloy AZ31 obtained from the step (3) to room temperature. A method for manufacturing a small-peptide-coated biomaterial and an application of the small-peptide-coated biomaterial are further provided.

Abstract: Cartilage fibers and implants made therefrom are disclosed, with and without cartilage particles. Methods for making the cartilage fibers and the implants containing them are also disclosed. The implants may be pre-shaped, may be reshapable and, when implanted in a cartilage defect, the implants have good shape retention, little swelling, completely fill the cartilage defect and resist migration from the defect upon irrigation.

Abstract: Compositions comprising extracellular matrix (ECM) materials and methods of use thereof are disclosed. The compositions may comprise two or more ECM materials derived from different types of tissues, such as, e.g., lung tissue and spleen tissue, formulated for administration to a patient or configured as a medical device for implantation in or application to the patient. The compositions may combine complementary properties of different types of ECM materials for customized patient-specific and/or site-specific tissue repair and/or regeneration.

Abstract: Provided are a method for fabricating a human nasal turbinate-derived mesenchymal stem cell-based 3D bioprinted construct, and a use thereof, wherein the human nasal turbinate-derived mesenchymal stem cell-based, 3D bioprinted construct is advantageous over conventional mesenchymal stem cell-based, 3D bioprinted constructs in that the former can survive and proliferate stably in vitro and/or in vivo and shows high osteogenic differentiation ability as well, therefore is expected to make a great contribution to the practical use of cellular therapeutic agents.